Advertisement

Introduction: Historical Background

  • Jean-Françcois JeanninEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 667)

Abstract

Treatment of cancer patients with lipid A analogs is now feasible. This is the culmination of a long story, beginning hundreds of years ago, of progress in different scientific fields bacteriology, chemistry, immunology, genetics, cell biology and experimental medicine. Knowing the history of this domain of research is important in understanding why there is increasing acceptance among the scientific community of attempts to treat cancer with lipid A analogs.

Keywords

Adaptive Immune System Serratia Marcescens Innate Immune Cell Treat Cancer Patient Danger Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Galanos C, Lehmann V, Luderitz O et al. Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A. Eur J Biochem 1984; 140:221–227.CrossRefPubMedGoogle Scholar
  2. 2.
    Takayama K, Qureshi N, and Mascagni P et al. Complete structure of lipid A obtained from the lipopolysaccharides of the heptoseless mutant of Salmonella typhimurium. J Biol Chem 1983; 258:12801–12803.PubMedGoogle Scholar
  3. 3.
    Sultzer B M. Genetic control of leucocyte responses to endotoxin. Nature 1968; 219:1253–1254.CrossRefPubMedGoogle Scholar
  4. 4.
    Rosenstreich DL, Vogel SN, Jacques AR., Wahl LM et al. Macrophage sensitivity to endotoxin: genetic control by a single codominant gene. J Immunol 1978; 121:1664–1670.PubMedGoogle Scholar
  5. 5.
    Wright SD, Tobias PS, Ulevitch RJ et al. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med 1989; 170:1231–1241.CrossRefPubMedGoogle Scholar
  6. 6.
    Wright SD, Ramos RA, Tobias PS et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431–1433.CrossRefPubMedGoogle Scholar
  7. 7.
    Medzhitov R, Preston-Hurlburt P and Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394–397.CrossRefPubMedGoogle Scholar
  8. 8.
    Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/I0ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085–2088.CrossRefPubMedGoogle Scholar
  9. 9.
    Bretscher P, and Cohn M. A theory of self-nonself discrimination. Science 1970; 169:1042–1049.CrossRefPubMedGoogle Scholar
  10. 10.
    Medzhitov R, and Janeway CA, Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9:4–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Medzhitov R, and Janeway, CA, Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998; 10:351–353.CrossRefPubMedGoogle Scholar
  12. 12.
    Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301–305.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Tumor Immunology and Immunotherapy Laboratory Ecole Practique des Hautes Etudes Inserm U866University of BurgundyDijonFrance

Personalised recommendations